JP2007532582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532582A5 JP2007532582A5 JP2007507578A JP2007507578A JP2007532582A5 JP 2007532582 A5 JP2007532582 A5 JP 2007532582A5 JP 2007507578 A JP2007507578 A JP 2007507578A JP 2007507578 A JP2007507578 A JP 2007507578A JP 2007532582 A5 JP2007532582 A5 JP 2007532582A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- hydrogen
- optionally substituted
- halo
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001931 aliphatic group Chemical group 0.000 claims 82
- 239000001257 hydrogen Substances 0.000 claims 59
- 229910052739 hydrogen Inorganic materials 0.000 claims 59
- 125000005843 halogen group Chemical group 0.000 claims 47
- 125000000623 heterocyclic group Chemical group 0.000 claims 47
- 125000001072 heteroaryl group Chemical group 0.000 claims 32
- -1 —OR 7 Chemical group 0.000 claims 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 30
- 150000002431 hydrogen Chemical class 0.000 claims 25
- 125000004452 carbocyclyl group Chemical group 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 23
- 229910052757 nitrogen Inorganic materials 0.000 claims 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 19
- 125000001188 haloalkyl group Chemical group 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 13
- 125000002947 alkylene group Chemical group 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 125000002950 monocyclic group Chemical group 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 0 CC1(C)OC[C@@](C(Nc2cc(Cl)cc3c2[n]c2cnccc32)=O)N(CC(Nc2cnccn2)=*)C1 Chemical compound CC1(C)OC[C@@](C(Nc2cc(Cl)cc3c2[n]c2cnccc32)=O)N(CC(Nc2cnccn2)=*)C1 0.000 description 2
- JQLQLGAJYLEICO-UHFFFAOYSA-O CC1(C)OCC(C(Nc2cc(Cl)cc-3c2[NH2+]c2cnccc-32)=O)N(CC(NC2CCNCC2)=O)C1 Chemical compound CC1(C)OCC(C(Nc2cc(Cl)cc-3c2[NH2+]c2cnccc-32)=O)N(CC(NC2CCNCC2)=O)C1 JQLQLGAJYLEICO-UHFFFAOYSA-O 0.000 description 1
- UYSYBZVVDDYMQT-UHFFFAOYSA-N CC1(C)OCC(C(Nc2cc(Cl)cc3c2[nH]c2c3C=CNC2)=O)N(CC(N(CC2)CCC2NC(C)=O)=O)C1 Chemical compound CC1(C)OCC(C(Nc2cc(Cl)cc3c2[nH]c2c3C=CNC2)=O)N(CC(N(CC2)CCC2NC(C)=O)=O)C1 UYSYBZVVDDYMQT-UHFFFAOYSA-N 0.000 description 1
- CAJKVRMMTHEDFG-UHFFFAOYSA-N CC1(C)OCC(C(Nc2cc(Cl)cc3c2[nH]c2cnccc32)=O)N(CC(N(CC2)CCC2C(F)(F)F)=O)C1 Chemical compound CC1(C)OCC(C(Nc2cc(Cl)cc3c2[nH]c2cnccc32)=O)N(CC(N(CC2)CCC2C(F)(F)F)=O)C1 CAJKVRMMTHEDFG-UHFFFAOYSA-N 0.000 description 1
- NHYQIFWNYYCDNI-UHFFFAOYSA-N CC1(C)OCC(C(Nc2cc(Cl)cc3c2[nH]c2cnccc32)=O)N(CC(NC(CC2)CCN2C(C)=O)=O)C1 Chemical compound CC1(C)OCC(C(Nc2cc(Cl)cc3c2[nH]c2cnccc32)=O)N(CC(NC(CC2)CCN2C(C)=O)=O)C1 NHYQIFWNYYCDNI-UHFFFAOYSA-N 0.000 description 1
- PLPDRQMNKXHSOB-DEOSSOPVSA-N CC1(C)OC[C@@H](C(Nc2cc(Cl)cc3c2[nH]c2cnccc32)=O)N(CC(N2CCC(C[N+](C)(C)[O-])CC2)=O)C1 Chemical compound CC1(C)OC[C@@H](C(Nc2cc(Cl)cc3c2[nH]c2cnccc32)=O)N(CC(N2CCC(C[N+](C)(C)[O-])CC2)=O)C1 PLPDRQMNKXHSOB-DEOSSOPVSA-N 0.000 description 1
- HWBCEOSXWUVELS-NRFANRHFSA-N CC1(C)OC[C@@H](C(Nc2cc(Cl)cc3c2[nH]c2cnccc32)=O)N(CC(NN2CCCCC2)=O)C1 Chemical compound CC1(C)OC[C@@H](C(Nc2cc(Cl)cc3c2[nH]c2cnccc32)=O)N(CC(NN2CCCCC2)=O)C1 HWBCEOSXWUVELS-NRFANRHFSA-N 0.000 description 1
- JXCMZOYCAKYXPM-JOCHJYFZSA-N CC1(C)OC[C@H](C(Nc2cc(Cl)cc3c2[nH]c2cnccc32)=O)N(CC[NH+](c(cn2)ccc2OC)[O-])C1 Chemical compound CC1(C)OC[C@H](C(Nc2cc(Cl)cc3c2[nH]c2cnccc32)=O)N(CC[NH+](c(cn2)ccc2OC)[O-])C1 JXCMZOYCAKYXPM-JOCHJYFZSA-N 0.000 description 1
- XBPSLHXWTIIWFA-QGZVFWFLSA-N CCOC(CN(C)C(CN1[C@H](C[NH+](c2cc(Cl)cc3c2[nH]c2cnccc32)[O-])COC(C)(C)C1)=O)=O Chemical compound CCOC(CN(C)C(CN1[C@H](C[NH+](c2cc(Cl)cc3c2[nH]c2cnccc32)[O-])COC(C)(C)C1)=O)=O XBPSLHXWTIIWFA-QGZVFWFLSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56089204P | 2004-04-09 | 2004-04-09 | |
| PCT/US2005/013812 WO2005111037A1 (en) | 2004-04-09 | 2005-04-08 | Beta-carbolines useful for treating inflammatory disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532582A JP2007532582A (ja) | 2007-11-15 |
| JP2007532582A5 true JP2007532582A5 (https=) | 2008-03-13 |
Family
ID=35045213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007507578A Pending JP2007532582A (ja) | 2004-04-09 | 2005-04-08 | 炎症性疾患の処置に有用なβ−カルボリン |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7951801B2 (https=) |
| EP (2) | EP1735311B1 (https=) |
| JP (1) | JP2007532582A (https=) |
| KR (1) | KR20070014166A (https=) |
| CN (1) | CN1976931A (https=) |
| AT (1) | ATE462702T1 (https=) |
| AU (1) | AU2005243188A1 (https=) |
| BR (1) | BRPI0509660A (https=) |
| CA (1) | CA2561859A1 (https=) |
| CR (1) | CR8696A (https=) |
| DE (1) | DE602005020263D1 (https=) |
| EA (1) | EA010546B1 (https=) |
| EC (1) | ECSP066986A (https=) |
| IL (1) | IL178435A0 (https=) |
| MA (1) | MA28567B1 (https=) |
| MX (1) | MXPA06011545A (https=) |
| NO (1) | NO20064894L (https=) |
| RS (1) | RS20060584A (https=) |
| TN (1) | TNSN06321A1 (https=) |
| TW (1) | TW200539880A (https=) |
| UA (1) | UA88638C2 (https=) |
| WO (1) | WO2005111037A1 (https=) |
| ZA (1) | ZA200608956B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| WO2007118854A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| US8791264B2 (en) * | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| AR063275A1 (es) * | 2006-10-12 | 2009-01-14 | Epix Delaware Inc | Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2. |
| WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| US20090137579A1 (en) * | 2007-10-23 | 2009-05-28 | Millennium Pharmaceuticals, Inc. | Mesylate salt of an IKK inhibitor |
| US20090131422A1 (en) * | 2007-10-23 | 2009-05-21 | Millennium Pharmaceuticals, Inc. | Salts of an IKK inhibitor |
| BRPI0820701A2 (pt) | 2007-12-11 | 2015-06-16 | Cytopathfinder Inc | Composto de carboxamida e seu uso como agonistas do receptor de quimiocina |
| ES2693247T3 (es) | 2010-07-06 | 2018-12-10 | Ono Pharmaceutical Co., Ltd. | Derivado de tetrahidrocarbolina |
| WO2012127885A1 (ja) | 2011-03-18 | 2012-09-27 | 小野薬品工業株式会社 | テトラヒドロカルボリン誘導体 |
| CN102416014B (zh) * | 2011-09-13 | 2012-11-21 | 河南中医学院 | 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用 |
| WO2017067670A1 (en) | 2015-10-23 | 2017-04-27 | Pharmathen S.A. | A novel process for the preparation of tryptamines and derivatives thereof |
| AU2017225912B2 (en) | 2016-03-03 | 2022-02-17 | Bill Elliot Cham | Glycoalkaloid combinations and various uses thereof |
| US11117893B2 (en) * | 2018-09-24 | 2021-09-14 | Union University | Methods for preparation of substituted pyridines and related novel compounds |
| WO2022223022A1 (zh) * | 2021-04-23 | 2022-10-27 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2242402T3 (es) | 1998-08-12 | 2005-11-01 | Pfizer Products Inc. | Inhibidores de tace. |
| DE19951360A1 (de) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| HK1054039B (zh) * | 2000-03-15 | 2010-04-16 | 萨诺费－阿文蒂斯德国有限公司 | 取代的β-咔啉 |
| EP1268477B1 (en) * | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| ATE363473T1 (de) | 2001-09-19 | 2007-06-15 | Pharmacia Corp | Substituierte pyrazoloverbindungen zur behandlung von entzündungen |
| US9248124B2 (en) | 2001-11-07 | 2016-02-02 | Millennium Pharmaceuticals, Inc. | Use of inhibitors of IκB kinase for the treatment of cancer |
| BRPI0409263A (pt) | 2003-04-09 | 2006-03-28 | Millennium Pharm Inc | composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita |
-
2005
- 2005-04-08 BR BRPI0509660-0A patent/BRPI0509660A/pt not_active IP Right Cessation
- 2005-04-08 EP EP05779267A patent/EP1735311B1/en not_active Expired - Lifetime
- 2005-04-08 MX MXPA06011545A patent/MXPA06011545A/es not_active Application Discontinuation
- 2005-04-08 TW TW094111190A patent/TW200539880A/zh unknown
- 2005-04-08 JP JP2007507578A patent/JP2007532582A/ja active Pending
- 2005-04-08 WO PCT/US2005/013812 patent/WO2005111037A1/en not_active Ceased
- 2005-04-08 UA UAA200611756A patent/UA88638C2/ru unknown
- 2005-04-08 EA EA200601884A patent/EA010546B1/ru not_active IP Right Cessation
- 2005-04-08 US US11/101,998 patent/US7951801B2/en not_active Expired - Lifetime
- 2005-04-08 EP EP10003450A patent/EP2206713A1/en not_active Withdrawn
- 2005-04-08 AT AT05779267T patent/ATE462702T1/de not_active IP Right Cessation
- 2005-04-08 AU AU2005243188A patent/AU2005243188A1/en not_active Withdrawn
- 2005-04-08 DE DE602005020263T patent/DE602005020263D1/de not_active Expired - Fee Related
- 2005-04-08 KR KR1020067023401A patent/KR20070014166A/ko not_active Ceased
- 2005-04-08 CA CA002561859A patent/CA2561859A1/en not_active Abandoned
- 2005-04-08 RS RSP-2006/0584A patent/RS20060584A/sr unknown
- 2005-04-08 CN CNA2005800190147A patent/CN1976931A/zh active Pending
-
2006
- 2006-10-04 IL IL178435A patent/IL178435A0/en unknown
- 2006-10-06 TN TNP2006000321A patent/TNSN06321A1/en unknown
- 2006-10-19 CR CR8696A patent/CR8696A/es unknown
- 2006-10-26 NO NO20064894A patent/NO20064894L/no not_active Application Discontinuation
- 2006-10-27 ZA ZA200608956A patent/ZA200608956B/en unknown
- 2006-11-02 MA MA29431A patent/MA28567B1/fr unknown
- 2006-11-09 EC EC2006006986A patent/ECSP066986A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532582A5 (https=) | ||
| HRP20100670T1 (hr) | Aril-supstituirani pirazol-amid spojevi korisni kao inhibitori kinaze | |
| JP2005511532A5 (https=) | ||
| RU2003128992A (ru) | Омега-аминоалкиламиды r-2-арилпропионовых кислот в качестве ингибиторов хемотаксиса полиморфноядерных и одноядерных клеток | |
| UA102088C2 (ru) | Производные n-азабициклических карбоксамидов, их получение и применение в терапии | |
| JP2005511531A5 (https=) | ||
| JP2011510080A5 (https=) | ||
| JP2010509375A5 (https=) | ||
| JP2005519932A5 (https=) | ||
| NO20073667L (no) | [4-(heteroaryl) piperazin-1-yl]-(2,5-substituert-fenyl)metanonderivater som glycintransportor 1(GLYT-1)- inhibitorer for behandling av neurologiske og neuropsykiatriske lidelser | |
| JP2014517017A5 (ja) | 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用 | |
| RU2004113099A (ru) | Четвертичные аммониевые соли омега-аминоалкиламидов r-2- арилпропионовых кислот и содержащие их фармацевтические составы | |
| JP2008513498A5 (https=) | ||
| DE602004031722D1 (de) | Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden | |
| JP2005505618A5 (https=) | ||
| EA200300424A1 (ru) | Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов | |
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| JP2006522824A5 (https=) | ||
| RU2006102127A (ru) | Производные хинолина и их применение в терапии | |
| JP2008513432A5 (https=) | ||
| WO2010000030A1 (en) | Thiazopyrimidinones and uses thereof | |
| JP2021535087A5 (https=) | ||
| ATE318266T1 (de) | 3-substituierte chinolin-4- carbonsäureamidderivate als nk-3- und nk-2- rezeptorantagonisten | |
| Su et al. | Discovery of biphenyl-aryl ureas as novel VEGFR-2 inhibitors. Part 4: exploration of diverse hinge-binding fragments | |
| EA200601880A1 (ru) | Замещенные производные 4-алкил- и 4-алканоилпиперидина и их применение в качестве антагонистов нейрокининов |